Combinatorial Purine Libraries As Inhibitors Of Cyclin Dependent Kinases
Inhibitors for protein kinasesAnalysis of signal transduction pathwaysTherapeuticsLicenses are available in fields EXCEPT for neurodegenerative disease
None
Patent Number: US6255485B1
Application Number: US1998130255A
Inventor: Gray, Nathanael S. | Schultz, Peter | Kim, Sung Hou | Meijer, Laurent
Priority Date: 7 Aug 1997
Priority Number: US6255485B1
Application Date: 6 Aug 1998
Publication Date: 3 Jul 2001
IPC Current: A61K003152 | A61P002528 | A61P003500 | C07D047316
US Class: 544277
Assignee Applicant: The Regents of the University of California | Centre National de la Recherche Scientifique,Paris
Title: Purine inhibitors of protein kinases, G proteins and polymerases
Usefulness: Purine inhibitors of protein kinases, G proteins and polymerases
Summary: USE (I) are used in the treatment of atherosclerosis, solid tumours and tumour metastasis, benign tumours, e.g. hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, vascular malfunctions, abnormal wound healing, immune and inflammatory disorders, Bechet's disease, gout, gouty or rheumatoid arthritis, psoriasis, diabetic or other retinopathy, macular degeneration, corneal graft rejection, neuroscular glaucoma, Oster-Webber syndrome, restenosis, or fungal, parasitic, and viral infections. Typical tumours inhibited are those of lung, breast, colon, ovary, prostate, and hepatic cells. They are also used in the treatment of neurodegenerative diseases such as Alzheimer's, Alper's, and Leigh's diseases, AIDS-related dementia, Lewy body disease, epilepsy, multiple system atrophy, Guillain-Barre syndrome, lipofuchsinosis, Down's syndrome, and vertigo. (I) are used to treat laboratory and farm animals and domestic pets, and even inhibition of undesirable growth of plants. (I) can also be used as molecular tools and probes in research. They can be used alone, or in combination therapy with other, known, drugs, particularly chemotherapeutic and antineoplastic compounds.
Novelty: New 6-Arylamino-2-hydroxyalkylaminopurine derivatives of olomoucine are cellular kinase, G protein, and polymerase inhibitors, for treating e.g. cancer, arthritis and psoriasis
诊断/治疗
癌症/肿瘤
6255485
Tech ID/UC Case 18502/1997-072-0 Related Cases 1997-072-0
美国
